CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment (Q34381754)

1 August 2017

title

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment (English)

1 reference

1 August 2017

1 reference

1 reference

16

Richard M Weinshilboum

1 reference

1 August 2017

19

David A Flockhart

1 reference

1 August 2017

2

Zeruesenay Desta

1 reference

1 August 2017

3

Vered Stearns

1 reference

1 August 2017

Anna Maria V. Storniolo

8

object named as

Anna Maria Storniolo

1 reference

1 August 2017

12

Anne Nguyen

1 reference

1 August 2017

15

Suzanne Lemler

1 reference

1 August 2017

14

Jill Hayden

1 reference

1 August 2017

7

Todd Skaar

1 reference

1 August 2017

17

James M Rae

1 reference

1 August 2017

Yan Jin

1

1 reference

1 August 2017

Bryan Ward

4

1 reference

1 August 2017

Herbert Ho

5

1 reference

1 August 2017

Kyung-Hoon Lee

6

1 reference

1 August 2017

Lang Li

9

1 reference

1 August 2017

Adjei Araba

10

1 reference

1 August 2017

Rebecca Blanchard

11

1 reference

1 August 2017

Lynda Ullmer

13

1 reference

1 August 2017

Daniel F Hayes

18

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Journal of the National Cancer Institute

1 August 2017

published in

1 reference

1 August 2017

volume

97

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

30-39

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

4-Hydroxytamoxifen sulfation metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Tamoxifen-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Phase III evaluation of fluoxetine for treatment of hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI005

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJI005

1 reference

1 August 2017

1 reference